GLP-1s - which mimic the effects of the hormone that stimulates insulin release, suppressing glucagon, and slowing gastric emptying - also have a range of other benefits.

The Canadian researcher has just received the Frontiers of Knowledge Award for his work on anti-obesity drugs. However, he ...

New research published Tuesday concludes that the rising rate of extreme childhood obesity—well above the usual BMI ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver disease and type 2 diabetes ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

More than 40% of Americans are obese, according to the Centers for Disease Control and Prevention (CDC). And the epidemic isn ...

Dear J.H.: Metformin, a treatment for diabetes that works mostly by preventing the liver from making sugar, isn't new and has ...

I am a 75-year-old woman who isn’t prediabetic or diabetic. My BMI is 31.2. My doctor has prescribed a trial of metformin for ...

More scientific evidence is emerging to show that our gastrointestinal system interacts with our nervous system ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...